seekingalpha comments, page-5

Anjo-Roch,

I submitted the seekingalpha post because it pointed out the weakness of the small sample results, and the risk still in the full scale clinical trial. The author, Martin Shkreli, had two major faults in his analysis; he failed to consider that the MPC treated group deaths were not cardiac related, and he completely ignored the positive results of adverse cardiac events, which had very low p values. His 95% drop assumed a complete failure of all MPC applications, and is ridiculous.
I should have mentioned these problems, but it was very early in the morning.

The author has correctly described the problem of dealing in a US pink sheet version of an Australian stock. I tried to sell some Mesoblast shares (5 share blocks), at 60 cents below the Australian close, and had no takers. I will try again tomorrow (Friday here). I have a short term use for the money now, but will put it back soon.

I had also seen the Athersys article you mentioned. This seems to be by a different author, who did a much better job of analyzing his subject. I did a little investigation, and decided that Athersys is a year or two behind. I might invest in them in a few years.